Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.

导出 LinkOut

翻译打印收藏纠错

作者： Cullen L,Myers ^[1] ; Annie,Stevenson ^[2] ; Brittany,Miller ^[2] ; Denis M,Daigle ^[2] ; Tsuyoshi,Uehara ^[2] ; Daniel C,Pevear ^[2]

作者单位： Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.;Venatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA. ^[1] Venatorx Pharmaceuticals Inc., Malvern, Pennsylvania, USA. ^[2]

关键词 KPC antibiotic resistance ceftazidime–avibactam ledaborbactam taniborbactam β-lactamase inhibitor

DOI 10.1128/aac.01511-24

PMID 39927783

发布时间 2025-02-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Antimicrobial agents and chemotherapy

e0151124页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.

Antimicrobial agents and chemotherapy

相似文献

Antimicrobial agents and chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.

Antimicrobial agents and chemotherapy

相似文献

Antimicrobial agents and chemotherapy

相关期刊

检索历史清除